Creative Biogene Expands Antibody Purification Platform to Support Biotechnology Innovation
Creative Biogene's enhanced antibody purification platform offers scalable, high-yield purification solutions critical for advancing biotech research and development.
Creative Biogene has expanded its antibody purification platform, providing a streamlined workflow for producing high-yield, high-purity antibodies through scalable and customizable protocols. This development addresses the growing industry need for consistent and efficient antibody preparations, supporting both companies and research institutions in their biotechnology innovation efforts.
The platform features a comprehensive purification workflow incorporating capture, intermediate, and polishing steps. It utilizes Protein A/G/L resins for Fc-binding antibodies, ion exchange chromatography for charge-based purification, and size exclusion chromatography for aggregate removal, ensuring final antibody purity exceeding 95%. Additional processes include hydrophobic interaction chromatography, multimodal approaches, and buffer exchange capabilities.
Quality control services complement the purification process, featuring SDS-PAGE, SEC-HPLC, and endotoxin testing with results delivered in detailed Certificate of Analysis reports. The platform's equipment includes compact, easy-to-operate chromatography columns and process chromatography systems available at both laboratory and pilot scales, allowing for customizable system designs that adapt to various research needs.
Buffer dilution and conditioning systems enable precise formulation while reducing resource consumption, and filtration systems—including tangential flow, depth filtration, and single-use options—ensure rapid turnaround between purification runs. This integrated approach provides researchers with a complete and flexible solution for antibody purification across multiple applications.
The platform supports various biotechnology applications, including antibody candidate development programs, assay optimization, production of kit components, and research reagents. According to Marcia Brady's Chief Expert, the platform's main value lies in its well-balanced throughput and reproducibility, having been optimized to deliver consistent results across different scales and antibody targets.
Creative Biogene continues to invest in platform improvements, focusing on enhanced automation features and increased scalability. Through future integration and ongoing refinement of purification protocols and scalable designs, the company aims to provide comprehensive solutions that meet current and emerging research requirements in the biotechnology sector. For additional details, visit https://www.creative-biogene.com/services/antibody-purification.html.